Entity
  • Altevax Biotech

    Created in 2016
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    678
  • Activities

  • Technologies

  • Entity types

  • Location

    55 Av. Marceau, 75116 Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 6

  • SIREN

    823688502
  • Engaged corporates

    10
    2 5
  • Added in Motherbase

    10 months, 2 weeks ago
Description
  • Value proposition

    Altevax is developing a disruptive immunotherapy technology against cancer

    Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.

    Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024.

    Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.

    Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T cells, and Immuno-oncology

  • Original language

    Altevax is developing a disruptive immunotherapy technology against cancer

    Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.

    Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024.

    Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.

  • Altevax | A first-in-class immunotherapy against cancer

    Using melanin as an adjuvant, Altevax has developed an immunotherapy that triggers a strong antigen-specific immune response of CD8+ and CD4+ T cells. Altevax is committed to bringing its innovative anticancer and anti-infectious technology to patients, to treat diseases that have no available cure today.

  • https://www.altevax.com/
Corporate interactions BETA
Corporate TypeTweets Articles
SATT AxLR SATT AxLR
Other

29 May 2024


BioValley France
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Other

29 May 2024


Business France
Business France
National and local authorities, Government Administration
Business France
National and local authorities, Government Administration
Other

5 Jun 2024


CNRS
CNRS
Research, Research Services
CNRS
Research, Research Services
Other

22 May 2024


Viva Technology
Viva Technology
Trade show, IT Services and IT Consulting
Viva Technology
Trade show, IT Services and IT Consulting
Other

22 May 2024


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Other

22 May 2024


CCI Paris IdF
CCI Paris IdF
Chamber of commerce, Government Administration
CCI Paris IdF
Chamber of commerce, Government Administration
Other

24 May 2024


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

5 Jun 2024


Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Other

5 Jun 2024


Greater Paris University Hospitals - AP-HP
Greater Paris University Hospitals - AP-HP
Health, Hospitals and Health Care
Greater Paris University Hospitals - AP-HP
Health, Hospitals and Health Care
Other

20 Jul 2023


Similar entities
Loading...
Loading...
Social network dynamics